Quarry Thera Secures $32M Series A Funding

Quarry Thera, a biotechnology company, has secured $32,000,000 in funding from investors.

This significant capital injection is poised to accelerate the development of its differentiated pipeline and unprecedented platform focused on proximity-induced therapeutics based on molecular glues.

The investment underscores confidence in the company’s innovative approach to drug discovery and its potential to address challenging medical conditions.

Founded by Mikael Dolsten, MD, PhD, former CSO & RD President of Pfizer, and Professor Craig M. Crews, Ph.D.

of Yale University, Quarry Thera is dedicated to advancing the next generation of molecular glue therapeutics.

The company's scientific leadership was recently bolstered by the addition of Jeanne Magram, PhD, who joined as Chief Scientific Officer. Dr.

Magram brings extensive experience in drug discovery, having held leadership roles at several top pharmaceutical companies and served as founding CSO for biotechs delivering therapeutics in immunology and oncology.

This expertise is vital for guiding Quarry Thera's ambitious research agenda.

Molecular glues have emerged as a powerful new modality in drug development, offering a novel way to target previously intractable proteins.

Quarry Thera employs a sophisticated methodology that combines proprietary DNA-encoded libraries, structurally enabled drug design, and advanced medicinal chemistry.

This integrated approach aims to overcome current limitations in therapeutic options, including issues with sub-optimal efficacy, narrow therapeutic windows, limited cellular permeability, and selectivity challenges, particularly when targeting proteins considered "undruggable.

"

The $32,000,000 in funding will be strategically deployed to expand Quarry Thera's research and development efforts, enhance its technological platform, and grow its specialized scientific team.

The company plans to accelerate the progression of its pipeline candidates and further solidify its position in the competitive biotech landscape.

This investment is expected to fuel Quarry Thera’s strategic growth and significantly advance its mission to develop groundbreaking proximity-induced therapeutics, ultimately aiming to deliver novel solutions for patients with high unmet medical needs.